VivoSeq
Other

CADASIL

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

CADASIL is an early-stage landscape with 6 programs across 4 companies. The most active players are Ever Neuro Pharma GmbH, Boehringer Ingelheim, Pfizer. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Ever Neuro Pharma GmbH

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Otsuka logo

Otsuka

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Unknown status1 · 20%
Active, not recruiting1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Safety Study of Dabigatran in CADASIL
Unknown status·SS. Andrea Hospital·Phase 2·NCT01361763·50 enrolled
Efficacy and Safety of Tocotrienols in CADASIL
Completed·—·Phase 2·NCT04658823·50 enrolled
CERebrolysin In CADASIL
Active, not recruiting·EEver Neuro Pharma GmbH·Phase 2·NCT05755997·30 enrolled
Adrenomedullin for CADASIL
Completed·NNational Cerebral and Cardiovascular Center, Japan·Phase 2·NCT06072118·60 enrolled
Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL: A Single-Center, Prospective, Single-Arm, Self-Controlled Clinical Trial.
Not yet recruiting·HHuashan Hospital·Phase 2·NCT07692399·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)